According to the prescribing information, patients treated with Spravato should receive a dose twice a week for the first ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Spravato was first approved by the FDA in 2019 ... distinct from ketamine and with different FDA-approved uses, dosing, and administration. Get the best tech, science, and culture news in your ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...

It's called Spravato, made by Johnson and Johnson and it works faster than standard oral antidepressants. Spravato was first approved back in 2019, but at that time, patients had to use it with an ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.